DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Zolinza (Vorinostat) - Summary

 
 



ZOLINZA SUMMARY

ZOLINZA contains vorinostat, an antineoplastic agent, which is described chemically as N- hydroxy- N'- phenyloctanediamide.

ZOLINZA1 is indicated for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive, persistent or recurrent disease on or following two systemic therapies.

ZOLINZA is a histone deacetylase (HDAC) inhibitor indicated for:

  • Treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistent or recurrent disease on or following two systemic therapies. (1)

See all Zolinza indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Zolinza (Vorinostat)

Mantle Cell Lymphoma (MCL)
Source: MedicineNet Aches, Pain, Fever Specialty [2014.09.09]
Title: Mantle Cell Lymphoma (MCL)
Category: Doctor's & Expert's views on Symptoms
Created: 9/9/2014 2:42:00 PM
Last Editorial Review: 9/9/2014 2:42:31 PM

Positive results announced for patients with aggressive non-Hodgkin's lymphoma
Source: Lymphoma / Leukemia / Myeloma News From Medical News Today [2014.08.27]
Phase 1-2a clinical trial highlights 12 of 13 Total Evaluable Patients with Advanced B Cell Malignancies Had Complete Remissions (8 Patients) or Partial Remissions (4 Patients) Resulting in a...

Predicting aggressive lymphoma by statistical genetic analysis
Source: Lymphoma / Leukemia / Myeloma News From Medical News Today [2014.08.27]
Each year, more than one thousand Norwegians develop lymphoma. A statistical genetic analysis can detect when the disease will be aggressive. Thereby, treatment can be initiated in time.

Study: race influences medical treatment offered by doctors in lymphoma patients
Source: Lymphoma / Leukemia / Myeloma News From Medical News Today [2014.08.12]
A new study published in a leading scientific journal has shown race can have a detrimental effect on medical treatment offered by doctors.

Lymphoma Treatment May Harm, Halt Men's Sperm Production
Source: MedicineNet Mens Health Specialty [2014.07.28]
Title: Lymphoma Treatment May Harm, Halt Men's Sperm Production
Category: Health News
Created: 7/25/2014 2:36:00 PM
Last Editorial Review: 7/28/2014 12:00:00 AM

more news >>

Published Studies Related to Zolinza (Vorinostat)

A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia. [2010.07]
Histone deacetylase inhibitors (HDACi) affect chromatin remodelling and modulate the expression of aberrantly silenced genes. HDACi have single-agent clinical activity in haematological malignancies and have synergistic anti-leukaemia activity when combined with anthracyclines in vitro... The combination of vorinostat and idarubicin is generally tolerable and active in patients with advanced leukaemia and should be studied in the front-line setting.

Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. [2010.01.01]
PURPOSE Vorinostat, a histone deacetylase inhibitor, exerts anticancer effects by both histone and nonhistone-mediated mechanisms...

Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. [2010]
PURPOSE Vorinostat, a histone deacetylase inhibitor, exerts anticancer effects by both histone and nonhistone-mediated mechanisms...

A single supratherapeutic dose of vorinostat does not prolong the QTc interval in patients with advanced cancer. [2009.11.15]
CONCLUSIONS: Administration of a single supratherapeutic dose of the histone deacetylase inhibitor vorinostat is not associated with prolongation of the QTc interval. A dedicated QTc study in advanced cancer patients is a robust means for assessing risk for ventricular repolarization prolongation.

Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination. [2011.11.12]
Purpose Combining proteasome and histone deacetylase (HDAC) inhibition has been seen to provide synergistic anti-tumor activity, with complementary effects on a number of signaling pathways. The novel bi-cyclic structure of marizomib with its unique proteasome inhibition, toxicology and efficacy profiles, suggested utility in combining it with an HDAC inhibitor such as vorinostat...

more studies >>

Clinical Trials Related to Zolinza (Vorinostat)

Vorinostat Plus FND in Relapsed or Refractory Mantle Cell Lymphoma [Not yet recruiting]
1. Rationale In mantle cell lymphoma, the conventional chemotherapy achieves only temporary responses with a median duration of remissions only from 1 to 2 years. Therefore, mantle cell lymphoma is known as one of the B-cell lymphomas with poor prognosis. Although the treatment outcome of mantle cell lymphoma has been improved since intensive chemotherapy regimens such as HyperCVAD was used, a substantial number of patients are still frequently relapsed after chemotherapy. After relapse, most of them became refractory to various kinds of salvage treatment. That is why the results of most salvage chemotherapy regimens were disappointing. In addition, mantle cell lymphoma generally occurs in elderly people. Thus, intensive salvage chemotherapy may not be feasible for elderly patients. Therefore, an effective, novel combination treatment is urgently needed in relapsed or refractory mantle cell lymphoma patients.

2. Hypothesis

- Vorinostat will produce synergism with a combination treatment regimen

(Fludarabine, mitoxantrone, dexamethasone, FND) without overlapping toxicity

- Vorinostat maintenance treatment will reduce the relapse rate in patients

ineligible for autologous stem cell transplantation.

3. Purpose A phase II investigation to determin the effectiveness of vorinostat in combination with intravenous fludarabine, mitoxantrone, and dexamethasone in patients with relapsed or refractory mantle cell lymphomain patients with relapsed or refractory mantle cell lymphoma.

SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma [Recruiting]
The goal of this clinical research study is to find out how well the drug Zolinza (vorinostat) works in combination with the drug combination called CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) to treat patients with untreated T-cell NHL. The safety of these drugs in combination and the best dose of vorinostat when given in combination with CHOP will also be studied.

Objectives:

Primary Objectives:

Phase I:

1. Determine the toxicity profile and the maximum tolerated dose (MTD) of vorinostat when administered in combination with Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP)

Phase II:

2. To evaluate the progression free survival for patients with T-cell NHL receiving the combination of vorinostat and CHOP

Secondary Objectives (Phase I and II):

1. To evaluate the response rate for patients with T-cell NHL receiving the combination of vorinostat and CHOP.

2. To assess overall survival in patients with T-cell NHL treated with the combination of vorinostat and CHOP.

Study of Vorinostat Plus Capecitabine (X) and Cisplatin (P) for 1st Line Treatment of Metastatic or Recurrent Gastric Cancer [Recruiting]
There is scientific rationale for exploring the role of vorinostat, histone deacetylase inhibitor with capecitabine (X) and cisplatin (P), one of standard chemotherapy in patients with advanced gastric cancer. XP is a new standard of care in advanced gastric cancer (AGC) and vorinostat is a novel targeted agent that prevents tumor cell proliferation, survival and angiogenesis through histone deacetylase inhibition.

High-Dose or Low-Dose Vorinostat in Combination With Carboplatin or Paclitaxel in Treating Patients With Advanced Solid Tumors [Recruiting]
This randomized clinical trial is studying high-dose or low-dose vorinostat in combination with carboplatin or paclitaxel to see how well it works in treating patients with advanced solid tumors. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving different doses of vorinostat together with carboplatin or paclitaxel may kill more tumor cells

Ph I Vorinostat in the Treatment of Advanced Staged Oropharyngeal Squamous Cell Carcinoma [Recruiting]
RATIONALE: Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells. Giving vorinostat together with chemotherapy and radiation therapy may kill more tumor cells.

PURPOSE: This phase I trial is studying the side effects and best dose of vorinostat when given together with cisplatin and radiation therapy in treating patients with stage III or stage IVa squamous cell cancer of the oropharynx which is either unresectable or borderline resectable.

more trials >>

Reports of Suspected Zolinza (Vorinostat) Side Effects

Pyrexia (15)Decreased Appetite (12)Dehydration (10)Pneumonitis (9)Pleural Effusion (8)Febrile Neutropenia (8)Sepsis (8)Disease Progression (6)White Blood Cell Count Decreased (6)Renal Failure (6)more >>


Page last updated: 2014-09-09

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014